Novartis Needs A Bigger Safety Database For Menveo, FDA Says
Review of application for ages 11 and up proceeds, but the agency wants to see more data on infants, pushing a second filing for the meningitis vaccine to 2011 in the U.S.
Review of application for ages 11 and up proceeds, but the agency wants to see more data on infants, pushing a second filing for the meningitis vaccine to 2011 in the U.S.